Page 185 - CW E-Magazine (19-11-2024)

CPHI MILAN 2024

availability, stability and formulation complies with the most stringent qua- Market Manager at Seppic, com-
protection. This product thus comple- lity standards applied to active pharma- mented, “The launch of this new, high
ments Seppic’s Montanox injectable ceutical ingredients. It complies with value-added HPB reference is a signifi -
polysorbate range, used to solubilise Good Manufacturing Practice (GMP cant innovation in Seppic’s injectable
active pharmaceutical ingredients and Part II) and current Pharmacopeias in surfactants sector. It marks our deter-
formulate oil-in-water emulsions. force (EP, USP-NF, JP, CHP),” Seppic mination to develop ever more specifi c
informed. and qualitative ingredients for rapidly
“This new Montanox 20 HPB expanding markets such as the bio-
grade, like all products in the range, Mr. Hocine Nouari, Injectables logics market.”

DIVERSE OFFERING
Thermo Fisher Scientifi c showcases expanded

biopharma capabilities

US-based Thermo Fisher Scien- Development and Manufacturing GMP-certifi ed ultra-cold facility in
tifi c showcased its latest innovations Organisation (CDMO) and Contract Bleiswijk, Netherlands, innovative
supporting biotechnology and pharma- Research Organisation (CRO) drug label printing solutions and seamless
ceutical companies across indica- development solutions. It provides a packaging integration in Basel, Swit-
tions, modalities, sizes and stages of customisable suite of manufacturing, zerland, and expanded clinical trial
the drug development journey. clinical research and clinical supply logistics solutions in Buenos Aires,
chain services, including small mole- Argentina. The company opened an
“Thermo Fisher is transforming cule, biologics and cell and gene Innovation Lab in the US, to serve as
drug development and manufactur- therapies, supporting customers at a coworking lab space to create, test
ing processes to support customers every stage from pre-clinical to com- and validate services and solutions
as they move critical programmes mercialisation. that address common pain points
forward to tackle global health chal- across clinical trials.
lenges with speed, quality and effi - Expanding capabilities
ciency,” said Mr. Michael Shafer, To help accelerate pre-clinical oral To serve pharma and biotech cus-
Executive Vice President and Presi- drug development, Thermo Fisher tomers with advanced laboratory ser-
dent, biopharma services, Thermo has expanded two sites in the US to vices and instrumentation across all
Fisher Scientifi c. enable research and development, phases of pharmaceutical development,
manufacturing and testing of oral Thermo Fisher’s ‘PPD’ clinical re-
To help speed and simplify the solid dose drug formulations. search business is expanding its global
complex journey of drug discovery laboratory services with a new bioana-
and development, the company This year, the company also has lytical lab in GoCo Health Innovation
launched ‘Accelerator Drug Develop- invested in expanding its global clini- City in Gothenburg, Sweden, to help
ment’, Thermo Fisher’s 360° Contract cal trial network, including a new accelerate health innovation.
NEW PLATFORM

Enzene launches continuous manufacturing technology

for biologics

Enzene, a Pune-based CDMO and turing’ (FCCM) platform for commer- substance. “By employing high titer
part of Alkem Labs, launched its new cial biologics supply. clones, productivity and target protein
EnzeneX 2.0 technology at CPHI concentrations are improved, produc-
Milan. The patented technology is a According to the company, the new tion can be streamlined, and risks asso-
further evolution of the company’s ‘ platform provides uninterrupted pro- ciated with batch-to-batch transfers are
fully-connected continuous manufac- cessing, from perfusion to fi nal drug mitigated. Additionally, EnzeneX 2.0

Chemical Weekly November 19, 2024 185

Contents Index to Advertisers Index to Products Advertised